Breaking News Lyrica appeal refused in Europe

FibroAction have just been informed by Pfizer that their appeal to get marketing approval for Lyrica as a treatment for Fibromyalgia Syndrome (Fibro) in the EU has been rejected by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA).

This appeal followed the refusal in April of the European Medicines Agency (EMEA) to grant a marketing approval for Lyrica as a treatment for Fibro in Europe.

Currently, there are no treatments for Fibro which have European Marketing Approval. Lyrica, along with Cymbalta (Duloxetine) and Savella (Milnacipran) are approved by the American Food and Drug Administration (FDA) as treatments for Fibro.

More details to follow shortly.